SCHEMBL19040709

SCHEMBL19040709

CCCCCCCCCN(CCCCCCCC(=O)OC)CCC1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GNAI3 P08754 2/20 0.42
GNAO1 P09471 2/20 0.42
GNAI1 P63096 2/20 0.42
GPR119 Q8TDV5 6/20 0.42
FAAH O00519 1/20 0.41
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
GLS O94925 1/20 0.40
KDM4E B2RXH2 1/20 0.40
PKM P14618 1/20 0.40
ALDH1A1 P00352 1/20 0.39
BCHE P06276 2/20 0.38
ACHE P22303 2/20 0.38
EPHX1 P07099 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23606531 1.00 GNAI3 (0.42) GNAI3GNAO1GNAI1GPR119FAAH
SCHEMBL23576157 0.95 GNAI3 (0.40) GNAI3GNAO1GNAI1GPR119FAAH
SCHEMBL24113643 0.91 GPR119 (0.47) GNAI3GNAO1GNAI1GPR119FAAH
SCHEMBL24113637 0.91 GPR119 (0.47) GNAI3GNAO1GNAI1GPR119FAAH
SCHEMBL19040815 0.91 GPR119 (0.47) GNAI3GNAO1GNAI1GPR119FAAH
SCHEMBL19040848 0.91 GNAI3 (0.41) GNAI3GNAO1GNAI1GPR119FAAH
SCHEMBL19040882 0.90 GPR119 (0.47) GNAI3GNAO1GNAI1GPR119FAAH
SCHEMBL23606527 0.90 GPR119 (0.47) GNAI3GNAO1GNAI1GPR119FAAH
SCHEMBL19040827 0.90 GPR119 (0.47) GNAI3GNAO1GNAI1GPR119FAAH
SCHEMBL19040826 0.90 GPR119 (0.45) GNAI3GNAO1GNAI1GPR119FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3638678-B1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS MODERNATX INC (US) 2025-12-03 EP disclosed
EP-4036079-B1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS MODERNATX INC (US) 2025-11-19 EP disclosed
US-12396961-B2 Compounds and compositions for intracellular delivery of agents MODERNATX, INC. (US) 2025-08-26 US disclosed
EP-3394030-B2 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS MODERNATX INC (US) 2025-02-12 EP disclosed
US-12077501-B2 Compounds and compositions for intracellular delivery of agents MODERNATX, INC. (US) 2024-09-03 US disclosed
EP-4036079-A2 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS ModernaTX, Inc. (US) 2022-08-03 EP disclosed
EP-3394030-B1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS MODERNATX INC (US) 2021-12-22 EP disclosed
EP-3394030-B1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS MODERNATX INC (US) 2021-12-22 EP disclosed
US-20210198200-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS ARES CAPITAL CORPORATION, AS AGENT 2021-07-01 US disclosed
US-20210161829-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS ARES CAPITAL CORPORATION, AS AGENT 2021-06-03 US disclosed
US-10799463-B2 Compounds and compositions for intracellular delivery of agents MODERNATX, INC. (US) 2020-10-13 US disclosed
US-10195156-B2 Compounds and compositions for intracellular delivery of agents MODERNATX, INC. (US) 2019-02-05 US disclosed
US-20180369419-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS Moderna TX, Inc. (US) 2018-12-27 US disclosed
US-20180333366-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS ARES CAPITAL CORPORATION, AS AGENT 2018-11-22 US disclosed
WO-2017112865-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS MODERNATX, INC. (US) 2017-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10195156-B2 Compounds and compositions for intracellular delivery of agents LNPK, PLTP, PHOSPHO1 GNAI3 1599/4885GNAO1 3550/4885GNAI1 1739/4885
US-20210198200-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS LNPK, PLTP, PHOSPHO1 GNAI3 1599/4885GNAO1 3550/4885GNAI1 1739/4885
US-12396961-B2 Compounds and compositions for intracellular delivery of agents LNPK, PLTP, PHOSPHO1 GNAI3 1599/4885GNAO1 3550/4885GNAI1 1739/4885
US-20180369419-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS LNPK, PLTP, PHOSPHO1 GNAI3 1599/4885GNAO1 3550/4885GNAI1 1739/4885
US-20210161829-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS LNPK, PLTP, PHOSPHO1 GNAI3 1599/4885GNAO1 3550/4885GNAI1 1739/4885
US-20180333366-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS LNPK, PLTP, PHOSPHO1 GNAI3 1599/4885GNAO1 3550/4885GNAI1 1739/4885
US-12077501-B2 Compounds and compositions for intracellular delivery of agents LNPK, PLTP, PHOSPHO1 GNAI3 1599/4885GNAO1 3550/4885GNAI1 1739/4885
US-10799463-B2 Compounds and compositions for intracellular delivery of agents LNPK, PLTP, PHOSPHO1 GNAI3 1599/4885GNAO1 3550/4885GNAI1 1739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.